EMA Approval for Trazimera Marks Another Win for the Trastuzumab Biosimilars Market

Home » EMA Approval for Trazimera Marks Another Win for the Trastuzumab Biosimilars Market

EMA Approval for Trazimera Marks Another Win for the Trastuzumab Biosimilars Market

Pfizer’s breast cancer drug Trazimera has moved a step closer to joining Celltrion’s Herzuma, Amgen’s Kanjinti, and Merck Sharp & Dohme’s Ontruzant in the race to seize EU market share from Roche’s blockbuster Herceptin, says GlobalData, a leading data and analytics company.

In May 2018, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) positively recommended a marketing authorisation to be granted for Pfizer’s Trazimera (trastuzumab), a biosimilar to Herceptin (trastuzumab).

This news comes as a positive leap for Pfizer following its rejection from the FDA in April 2018, which included a request for additional technical information that was not related to the safety or clinical data submitted in the application.

Trazimera is indicated for the treatment of adult patients with HER2-positive metastatic and early breast cancer, as well as in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2-positive metastatic gastric cancer.

Tajekesa Chapman, PhD, Pharma Analyst at GlobalData, says: “Since its approval in 2000, Roche’s Herceptin is still leading the EU market for the HER2-positive breast cancer monoclonal antibodies. In 2017, it had sales of $2.2 billion, despite its 2014 European patent expiry and the imminent threat of these trastuzumab biosimilar intravenous formulations.”

“Roche is expected to maintain its dominance in the market owing to Herceptin’s combination use with other agents and the use of the subcutaneous formulation of the drug in the five major European markets (France, Germany, Italy, Spain, UK).”

If Trazimera’s sales begin in 2019, the biosimilar is forecast to reach European sales of $9 million in its first year, far below the predicted first year figures for Herzuma ($59 million), Kanjinti ($33 million), and Ontruzant ($20 million).

Although this lower projected revenue reflects Trazimera’s later entry in the trastuzumab biosimilar race, there is also speculation that Trazimera will offer a lower-cost option than current market players to remain competitive.

However, Trazimera’s pricing strategy has not yet been revealed. In the UK, a lower cost strategy would be supported, as biosimilar prescribing is being encouraged.

There are several initiatives under way from NHS England, the National Institute for Health and Care Excellence (NICE), and the British Oncology Pharmacy Association (BOPA) that support the commissioning and use of biosimilars, reducing barriers to uptake, and encouraging physicians to prescribe biosimilar alternatives where available.

In this regard, a vial of Trazimera would have to cost less than Herceptin’s £407.40 ($542.95) and Ontruzant’s £366.66 ($488.66).

Although Trazimera is Pfizer’s fourth biosimilar to receive a positive CHMP opinion from the EMA, it is the company’s first therapeutic oncology biosimilar. However, Trazimera is not the last trastuzumab biosimilar in the pipeline, as there are five others currently at different stages of development for the EU market.

Chapman concludes: “It remains to be seen whether Pfizer will commercialise Trazimera in other markets and whether the biosimilar stands a good chance for commercial success in the EU market, which is currently dominated by Herceptin and saturated with comparable biosimilars.”